Illumina, Inc. (ILMN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Illumina, Inc. (ILMN) Healthcare & Pipeline Overview

Illumina, Inc. stands at the forefront of genomic technology, delivering innovative sequencing and array-based solutions that empower researchers and clinicians to harness the power of genomics across multiple sectors, including life sciences and oncology.

What Is the Investment Thesis for ILMN?

Illumina, Inc. is poised for sustained growth, supported by its strong market position and innovative product offerings. The company boasts a market capitalization of $30.7B and a P/E ratio of 37.20, indicating a solid valuation relative to its earnings potential. Key growth catalysts include the increasing demand for genomic solutions in clinical settings, expansion into emerging markets, and advancements in sequencing technologies. The global genomics market is expected to grow significantly, providing ample opportunity for Illumina to capitalize on its leadership position. Additionally, the company maintains a high gross margin of 67.7%, reflecting its operational efficiency and pricing power. However, potential risks include competition from emerging technologies and regulatory challenges that could impact market access and product development timelines.

Based on FMP financials and quantitative analysis

ILMN Key Highlights

Market capitalization of $30.7B reflects strong investor confidence in genomic technologies.

• P/E ratio of 37.20 indicates a robust valuation relative to earnings, highlighting growth potential.
• Profit margin of 19.4% showcases operational efficiency in a competitive landscape.
• Gross margin of 67.7% exceeds industry averages, emphasizing pricing power and product demand.
• Beta of 1.49 suggests higher volatility compared to the market, indicating potential investment risks.

Who Are ILMN's Competitors?

ILMN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ILMN's Key Strengths?

Leading position in the genomic sequencing market with innovative technologies.

• High gross margins that reflect strong pricing power and operational efficiency.
• Diverse product portfolio catering to various healthcare and research applications.
• Strong customer base across multiple sectors, enhancing revenue stability.

What Are ILMN's Weaknesses?

Dependence on a limited number of products for a significant portion of revenue.

• High research and development costs impacting short-term profitability.
• Exposure to regulatory risks that could affect product approvals and market access.

What Could Drive ILMN Stock Higher?

Continued advancements in sequencing technology expected to drive product adoption.

• Expansion into emerging markets contributing to revenue growth.
• New product launches aimed at enhancing genomic analysis capabilities.
• Strategic partnerships with pharmaceutical companies to support drug development.

What Are the Key Risks for ILMN?

Rich valuation — a P/E of 37.20 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $490.0M recently.
• Regulatory challenges that could impact product approvals and market access.
• Intense competition from established players and new entrants in the genomics industry.
• Economic downturns affecting healthcare spending and investment in genomic technologies.

What Are the Growth Opportunities for ILMN?

• Growth opportunity 1: The global genomics market is projected to reach $62 billion by 2026, driven by increasing demand for personalized medicine and advanced diagnostic tools. Illumina's innovative sequencing technologies position it to capture significant market share, particularly in oncology and reproductive health applications, where genomic insights are critical for treatment decisions.
• Growth opportunity 2: Expansion into emerging markets, particularly in Asia-Pacific and Latin America, offers substantial growth potential. As healthcare infrastructure improves and genomic research gains traction in these regions, Illumina can leverage its established product portfolio to meet the rising demand for genomic solutions, potentially increasing revenue by 15-20% annually in these markets.
• Growth opportunity 3: Strategic partnerships with pharmaceutical and biotechnology companies for drug development and clinical trials can enhance Illumina's market presence. Collaborations in precision medicine initiatives are expected to drive revenue growth as the need for genomic data in drug development continues to rise, with potential contributions of $500 million in annual revenue by 2028.
• Growth opportunity 4: The increasing adoption of direct-to-consumer genetic testing presents a unique opportunity for Illumina.
• Growth opportunity 5: Advancements in sequencing technology, including improvements in speed and cost-effectiveness, are expected to drive greater adoption across clinical and research settings. Illumina's continuous investment in R&D positions it to lead in technological advancements, potentially increasing market penetration by 25% over the next five years.

What Threats Does ILMN Face?

• Intense competition from established players and new entrants in the genomics space.
• Rapid technological changes requiring continuous innovation and adaptation.
• Regulatory challenges that could impact product development timelines and market entry.

What Are ILMN's Competitive Advantages?

• Strong brand recognition and reputation in the genomics industry.
• Extensive patent portfolio protecting innovative technologies.
• Established relationships with key customers and partners in healthcare.
• High barriers to entry due to technological complexity and regulatory requirements.
• Robust R&D capabilities driving continuous innovation and product development.

What Does ILMN Do?

Illumina, Inc., founded in 1998 and based in San Diego, California, specializes in sequencing and array-based solutions for genetic and genomic analysis. The company's innovative products and services enable the widespread adoption of genomic solutions in various markets, including life sciences, oncology, reproductive health, and agriculture. Illumina's offerings include state-of-the-art instruments, consumables for genetic analysis, genotyping and sequencing services, and cancer detection testing services. These solutions are essential for genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical and biotechnology sectors. Over the years, Illumina has evolved from a niche player to a dominant force in the genomics industry, driven by its commitment to innovation and quality. The company markets its products directly to customers across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors in various global markets. Illumina's robust product portfolio and strategic partnerships position it favorably within the competitive landscape, allowing it to maintain a strong market presence and drive continued growth.

What Products and Services Does ILMN Offer?

• Provide advanced sequencing and array-based solutions for genetic and genomic analysis.
• Develop instruments and consumables essential for genetic analysis.
• Offer genotyping and sequencing services to various sectors.
• Deliver cancer detection testing services to healthcare providers.
• Engage in development and licensing agreements for genomic technologies.
• Market products directly and through distributors across global regions.

How Does ILMN Make Money?

• Generate revenue through the sale of sequencing instruments and consumables.
• Offer contract services for genotyping and sequencing to research institutions and hospitals.
• Engage in licensing agreements for proprietary genomic technologies.
• Provide cancer detection testing services as a direct offering to healthcare providers.
• Expand revenue streams through partnerships with pharmaceutical and biotechnology companies.

What Industry Does ILMN Operate In?

The medical diagnostics and research industry is experiencing rapid growth, driven by advancements in genomic technologies and increasing healthcare demands. The global genomics market is projected to expand significantly, with a compound annual growth rate (CAGR) of over 10% in the coming years. Illumina, Inc. is well-positioned within this landscape, leveraging its innovative solutions to capture market share from competitors such as Quest Diagnostics (DGX) and Labcorp (LH). As healthcare shifts towards personalized medicine, Illumina's focus on genomic analysis aligns with industry trends, enhancing its competitive advantage and market relevance.

Who Are ILMN's Key Customers?

• Genomic research centers and academic institutions.
• Government laboratories and public health organizations.
• Hospitals and clinical laboratories focused on diagnostics.
• Pharmaceutical and biotechnology companies involved in drug development.
• Commercial molecular diagnostic laboratories and consumer genomics companies.

Over the past six months, Illumina, Inc. insiders filed 97 SEC Form 4 transactions — 91 sales and 6 purchases. On net that is roughly 2.4M shares disposed (about $490.0M), a signal worth weighing alongside the fundamentals.

Illumina, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 10.3% above estimates on average.

Illumina, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.23 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Illumina, Inc. stands at 31.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 12.4%, showing how much profit it generates from its asset base. ILMN trades at a trailing price-to-earnings ratio of 37.20, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.6%, the inverse of the P/E and a quick read on earnings relative to price.

Illumina, Inc. (ILMN) Valuation Context

Valued at $30.7B, ILMN is classified as a large-cap stock. Analyst price targets span from $155.00 to $260.00, with a consensus of $210.67. At the current price of $202.98, that implies approximately 4% upside potential. Relative to its peer group, ILMN's quantitative score of 87/100 is above the peer average of 74/100.

ILMN Revenue & Earnings Trend

In Q2 FY2026, ILMN generated $1.16B in top-line revenue, marking a sequential increase of 6.2%. The company recorded net income of $207.0M, with diluted EPS of $1.35. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ILMN averaged $1.34 in diluted EPS.

Company Profile

Illumina, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Jacob Thaysen. ILMN has traded publicly since 2000.

ILMN Financials

ILMN Latest News

ILMN Analyst Consensus

ILMN MoonshotScore

Common Questions About ILMN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources